Aptar Pharma has acquired the clinical trial materials manufacturing capabilities of Mod3 Pharma (formerly Enteris Biopharma) from SWK Holdings.
Aptar will now operate an FDA-inspected, state-of-the-art facility in Boonton. The site includes cGMP cleanrooms, high-potency Active Pharmaceutical Ingredient (API) suites, biologics capabilities, and advanced fill-finish technologies-fully aligned with Aptar Pharma’s drug delivery solutions portfolio.
According to the company’s press release statement, the move addresses market demand for clinical trial material supply services, particularly for Phase 1 and 2 cGMP fill and finish services for orally inhaled nasal drug products (OINDPs).
“By integrating Phase 1 and 2 clinical manufacturing capabilities, we’re not just expanding our technical footprint – we’re deepening our commitment to customers seeking a seamless and accelerated path to market,” Gael Touya, president of Aptar Pharma, said.
